Latest News and Press Releases
Want to stay updated on the latest news?
-
SAN FRANCISCO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- New data from papers published in science and medical journals in 2024 shows tremendous growth in the evidence of efficacy of one particular brain...
-
Lublin, Poland, May 29, 2024 (GLOBE NEWSWIRE) -- noProblem, a leading English language school in Lublin, Poland, is excited to announce the launch of its range of online English courses. These...
-
ROCKVILLE, Md., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MarketResearch.com, the leading provider of market research solutions, announced today its commitment and progress toward developing an AI-driven...
-
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular...
-
SAN FRANCISCO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Despite the pandemic slowing scientific and medical studies, brain training research had another banner year. According to Posit Science, maker of...
-
Santa Monica, CA, March 07, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal...
-
Santa Monica, CA, Feb. 26, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
-
Santa Monica, CA, Feb. 20, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
-
Santa Monica, CA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
-
Santa Monica, CA, Feb. 05, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...